最新报道：According to Fortune, cancer drug developer MEI Pharma's stock price nearly doubled in the days leading up to its mid-July announcement of a $100 million crypto treasury strategy, despite no major updates filed with the U.S. Securities and Exchange Commission, no press releases, and virtually no discussion on social media. MEI Pharma wasn't the only company to experience unusual stock price increases before announcing a cryptocurrency purchase strategy. Fortune found similar patterns at other small public companies, which, according to finance professors, investors, and CEOs, suggests insiders gained early access to some announcements. "To me, this is definitely suspicious," said Xu Jiang, a professor at Duke University who studies insider trading in public markets. "From what I've seen, this is the case with many insider transactions," he said, adding that he couldn't confirm the existence of insider trading without a thorough investigation. A spokesperson for MEI Pharma declined to comment. Spokespeople for four other companies whose stock prices experienced unusual fluctuations before cryptocurrency purchases—Kindly MD, Empery Digital, Fundamental Global, and 180 Life Sciences Corp—did not respond to requests for comment. Spokespeople for VivoPower and Sonnet BioTherapeutics, two other cryptocurrency asset managers whose stock prices fluctuated similarly, also declined to comment. However, some of those who benefited from the cryptocurrency-related price increases weren't retail investors, but rather individuals with company connections or outsiders with access to private details who appeared to profit by being the first to report the news. SharpLink, an ETH treasury company, saw its stock price more than double from $3 to $6 in the three trading days before the announcement, despite not filing with the SEC or issuing a press release. "Word definitely leaked out, and it was hard to control because they were reaching so many investors," said the CEO of another cryptocurrency money manager involved in the transaction. The executive declined to be named when referring to a competitor.